Meeting
2022 ASCO Annual Meeting
Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.
Authors
Jarushka Naidoo
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD
Jarushka Naidoo , Scott Joseph Antonia , Yi-Long Wu , Byoung Chul Cho , Piruntha Thiyagarajah , Helen Mann , Michael David Newton , Corinne Faivre-Finn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02125461
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8541)
DOI
10.1200/JCO.2022.40.16_suppl.8541
Abstract #
8541
Poster Bd #
168
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Optimization of treatment options for EGFR-mutant, stage III, unresectable NSCLC: A systematic review and meta-analysis.
First Author: Lian Liu
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto
Poster
2023 ASCO Annual Meeting
EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).
First Author: Amin Nassar
Poster
2023 ASCO Annual Meeting
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
First Author: Benjamin Besse